Press Release

TaiGen files US IND for its influenza antiviral TG-1000

TAIPEI, Taiwan, Oct. 4, 2020 /PRNewswire/ — TaiGen Biotechnology Company, Limited (“TaiGen”) announced today that it has filed an Investigational New Drug (IND) application with the US FDA for its influenza antiviral TG-1000.

TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses. The first US patent for TG-1000 was successfully prosecuted and granted by the United States Patent and Trademark Office on Jan 14th, 2020.

A Phase 1 trial for in China was initiated by TaiGen in July 2020 and has successfully completed the first 4 groups in the single ascending dose part. A Phase 2 protocol has also been submitted to the institutional review board (IRB) of China-Japan Friendship Hospital in Beijing last month.

“We are excited about the IND filing in the US for the internally developed TG-1000 which has the potential to be a single dose treatment for influenza,” said Kuo-Lung Huang, the Chairman and CEO of TaiGen, “TG-1000 IND filing demonstrates yet again TaiGen’s capacity and experience in research and development of NCEs.”

About TaiGen Biotechnology
TaiGen Biotechnology is a leading research-based and market-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, China. In addition to TG-1000, TaiGen has three other in-house discovered NCEs: Taigexyn®, a novel non-fluorinated quinolone available in both oral and intravenous formulations, TG-3000, a chemokine receptor antagonist for stem cell transplantation and chemosensitization, and Furaprevir, a HCV protease inhibitor for treatment of chronic hepatitis infection. Taigexyn® is already on the market in the mainland China and Taiwan, TG-3000 has completed Phase 2 clinical studies, and Furaprevir is currently in Phase 3 clinical development.

SOURCE TaiGen

Medika Life

Medika Life is a digital Health Publication for both the medical profession and the public. Make informed decisions about your health and stay up to date with the latest developments and technological advances in the fields of medicine.

Recent Posts

Envisioning a Future with Reversal of Glaucoma-Related Vision Loss

More than 4.2 million Americans live with glaucoma, or about 1.6% of the country’s adult…

2 days ago

The Surprising Behavior That Raises Prostate Cancer Risk by Nearly Half

According to the American Cancer Society, prostate cancer is the most common cancer among men and…

2 days ago

Strength Beyond Years: How Exercise Redefines Aging

New research contradicting the myth that aging results in irretrievable muscle loss needs to confront…

1 week ago

No One Will Read This Article

Here’s the brutal truth about writing online in 2025: Nobody reads your blog posts.

2 weeks ago

Business of Health: When Patients Become Secondary to the System

Can the Health System Align Around a Common Goal — Better Health

2 weeks ago

Beans Are Now the Super Food That We All Need, So Get Ready for a New Diet

Beans are one of the best sources of protein and a food that can last…

2 weeks ago

This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.

Read More